

Chris Fegan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2243577/publications.pdf>

Version: 2024-02-01

84
papers

3,492
citations

218592

26
h-index

161767

54
g-index

85
all docs

85
docs citations

85
times ranked

6432
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanically Ventilated Patients Shed High-Titer Live Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for Extended Periods From Both the Upper and Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2022, 75, e82-e88.	2.9	8
2	Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1600.	1.7	6
3	Targeting the Non-Canonical NF- κ B Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1489.	1.7	6
4	Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 123-131.	0.8	31
5	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9
6	A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO Δ idel). <i>British Journal of Haematology</i> , 2021, 194, 69-77.	1.2	13
7	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	3.3	13
8	Increased frequency of CD4 ⁺ PD Δ 1 ⁺ HLA Δ DR ⁺ T cells is associated with disease progression in CLL. <i>British Journal of Haematology</i> , 2020, 188, 872-880.	1.2	18
9	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton Δ ™s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	3.3	15
10	Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. <i>Haematologica</i> , 2020, 105, 2868-2871.	1.7	2
11	Clinical utility of telomere length measurements in cancer. <i>Current Opinion in Genetics and Development</i> , 2020, 60, 107-111.	1.5	4
12	Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. <i>Function</i> , 2020, 1, zqaa002.	1.1	118
13	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020, 136, 17-18.	0.6	11
14	Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
15	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	0.8	197
16	Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF- κ B Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2127-2139.	2.9	17
17	Telomere fusions associate with coding sequence and copy number alterations in CLL. <i>Leukemia</i> , 2019, 33, 2093-2097.	3.3	9
18	Is venetoclax a new wonder drug in CLL?. <i>British Journal of Haematology</i> , 2019, 185, 643-646.	1.2	0

#	ARTICLE	IF	CITATIONS
19	A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, prolymphocytic leukaemia or mantle cell lymphoma. British Journal of Haematology, 2018, 182, 429-433.	1.2	23
20	Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 182, 344-359.	1.2	29
21	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3135-3135.	0.6	1
22	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. Journal of Clinical Oncology, 2018, 36, TPS7588-TPS7588.	0.8	6
23	Development and Characterisation of an in Vitro Model of Multiple Myeloma. Blood, 2018, 132, 4505-4505.	0.6	0
24	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5344-5344.	0.6	0
25	Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia, 2017, 31, 2085-2093.	3.3	27
26	Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology, 2017, 178, 240-249.	1.2	21
27	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood, 2017, 129, 2808-2810.	0.6	48
28	Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology, 2017, 178, 94-98.	1.2	26
29	Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. British Journal of Haematology, 2017, 176, 573-582.	1.2	13
30	PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS4059/ONO4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B-CELL MALIGNANCIES. Hematological Oncology, 2017, 35, 266-266.	0.8	1
31	Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. Oncotarget, 2017, 8, 11414-11424.	0.8	14
32	Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.. Journal of Clinical Oncology, 2017, 35, 7518-7518.	0.8	0
33	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016, 127, 411-419.	0.6	231
34	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood, 2016, 128, 563-573.	0.6	27
35	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 776-781.	2.0	14
36	Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Icicle Extension Study. Blood, 2016, 128, 2049-2049.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. <i>Blood</i> , 2016, 128, 2961-2961.	0.6	1
38	Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3233-3233.	0.6	2
39	In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length. <i>Blood</i> , 2016, 128, 350-350.	0.6	1
40	Genetic Analysis of Distinct Phenotypic Subsets within MM1.S Multiple Myeloma Cell Line Reveals the Pre-Existence of MM.1R-like Glucocorticoid Resistance and a Sub-Clone with an Activating PI3-Kinase Delta Mutation That Is Preferentially Sensitive to the Selective PI3-Kinase Inhibitor, Idelalisib. <i>Blood</i> , 2016, 128, 4449-4449.	0.6	0
41	A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. <i>Oncotarget</i> , 2015, 6, 32669-32680.	0.8	6
42	Understanding cancer cell survival is key to patient survival. <i>Lancet Oncology</i> , The, 2015, 16, 122-124.	5.1	20
43	Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. <i>Leukemia</i> , 2015, 29, 1602-1604.	3.3	214
44	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K γ inhibition. <i>Leukemia</i> , 2015, 29, 744-747.	3.3	20
45	Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. <i>Leukemia</i> , 2015, 29, 2411-2414.	3.3	42
46	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014, 167, 214-223.	1.2	73
47	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3607-3617.	0.6	31
48	The Bruton γ Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2014, 124, 3328-3328.	0.6	7
49	The Bruton γ tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL. <i>Journal of Clinical Oncology</i> , 2014, 32, 8553-8553.	0.8	5
50	CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161. <i>Blood</i> , 2014, 124, 3293-3293.	0.6	0
51	Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. <i>Nature Genetics</i> , 2013, 45, 1221-1225.	9.4	143
52	Apoptosis Deregulation in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 151-171.	0.8	8
53	Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. <i>Clinical Cancer Research</i> , 2012, 18, 678-687.	3.2	127
54	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012, 158, 589-599.	1.2	45

#	ARTICLE	IF	CITATIONS
55	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology, 2012, 159, 541-564.	1.2	127
56	Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia, 2012, 26, 826-830.	3.3	39
57	The Hsp90 inhibitor NVP-AUY922-AG inhibits NF- κ B signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget, 2012, 3, 525-534.	0.8	38
58	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology, 2011, 152, 570-578.	1.2	38
59	Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Cell Proliferation, 2011, 44, 380-390.	2.4	26
60	The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood, 2010, 116, 2968-2974.	0.6	49
61	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood, 2010, 116, 1899-1907.	0.6	148
62	Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- κ B Activation and <i>de novo</i> Gene Transcription. Cancer Research, 2010, 70, 7523-7533.	0.4	88
63	Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 763-769.	0.8	51
64	South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients. British Journal of Haematology, 2008, 142, 606-609.	1.2	26
65	The Novel Nuclear Factor- κ B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine. Clinical Cancer Research, 2008, 14, 8102-8111.	3.2	44
66	The NF- κ B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood, 2008, 111, 4681-4689.	0.6	145
67	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, 2008, 112, 3807-3817.	0.6	208
68	Pharmacological Inhibition of NF-KB Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells. Blood, 2008, 112, 380-380.	0.6	0
69	Rel a Is a Novel Prognostic Marker in CLL That Is Independent of VH Gene Mutation Status, CD38 Expression and ZAP-70 Expression. Blood, 2008, 112, 4153-4153.	0.6	0
70	Highly purified CD38+ and CD38 ^{low} sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia, 2007, 21, 687-696.	3.3	48
71	Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Therapeutic Endpoint for Relapsed CLL. Blood, 2007, 110, 3114-3114.	0.6	5
72	NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL. Blood, 2007, 110, 752-752.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Constitutive Nuclear p65 NF- κ B Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.. Blood, 2006, 108, 4974-4974.	0.6	0
74	BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma.. Blood, 2006, 108, 5022-5022.	0.6	1
75	Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.. Blood, 2006, 108, 2782-2782.	0.6	0
76	Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated. Journal of Clinical Oncology, 2005, 23, 1514-1521.	0.8	69
77	Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38+ Sub-Clones When Compared with CD38 ⁺ Sub-Clones Derived from the Same CLL Patient.. Blood, 2005, 106, 180-180.	0.6	2
78	ZAP-70 Expression Is More Predictive Than VH Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF- κ B Activation and CLL Cell Survival.. Blood, 2005, 106, 2942-2942.	0.6	0
79	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. Blood, 2005, 106, 2981-2981.	0.6	0
80	Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol. Cell Cycle, 2003, 2, 52-57.	1.3	21
81	All trans retinoic acid enhances human LAK activity. European Journal of Haematology, 1995, 54, 95-100.	1.1	8
82	In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1995, 16, 277-81.	1.3	7
83	Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia, 1995, 9, 2003-8.	3.3	83
84	The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplantation, 1990, 5, 373-7.	1.3	62